Article History
Received: 6 October 2020
Revised: 15 December 2020
Accepted: 6 January 2021
First Online: 8 February 2021
Change Date: 20 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-021-01520-9
Ethics approval and consent to participate
: This information was collected as part of a Clinical Effectiveness Project (Service Evaluation) registered at Weston Park Hospital, Sheffield, registration number 9977, approved by the Sheffield Teaching Hospitals Clinical Effectiveness Unit. The Clinical Effectiveness Unit did not require patients to provide written consent. There is no clinical trial number associated with this study. This study was performed in accordance with the Declaration of Helsinki.
: Data are available by request to the corresponding author.
: S.T.W. has no conflicts of interest to declare. S.E.B. has no conflicts of interest to declare. S.A.H. has been paid to lecture by Roche, MSD, AstraZeneca, BMS, Sotio, Janssen, Pierre Fabre, Ipsen, Pfizer. S.A.H. has received payment for advisory boards and consultancy from Roche, MSD, Astra Zeneca, Astellas, BMS, Pierre Fabre, Janssen, Pfizer, Bayer, GSK, Eisai.
: No funding was required for this project. S.A.H. has received funding from CRUK, MRC/NIHR, UHB charities, CCC charities, North West Cancer Research, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly.